KOMO BIOSCIENCES is a next-generation precision genome engineering technology company driven by the power of highly efficient, evolved integrases, a disruptive, unprecedented technology that can unlock significant opportunities in life sciences. Our mission is to advance the frontier of genetic engineering by developing innovative, high-efficiency gene editing technologies to enable precise and scalable genetic modifications empowering industries across healthcare, agriculture, and biotechnology to solve complex global challenges.
KOMO’s non-CRISPR, non-viral, non-nuclease gene engineering platform has demonstrated large gene insertion into a pre-defined, high-expressing region at up to 80% integration efficiency per chromosome in up to 96% of cells with unprecedented high efficiencies. The technology does not induce unprotected double strand DNA breaks thereby potentially addressing limitations of current gene engineering methods (CRISPR and its derivatives) with respect to off target editing, low efficiency, and inability to insert large fragments of DNA.
KOMO addresses four critical pain points: the need for site-specific, highly efficient, and safe genome insertion, urgency for accelerated manufacturing timelines, the need for non-viral delivery of cell and gene therapies, and the need for high integration efficiency for application in ex-vivo cell therapy. Additionally, KOMO’s technology enables rapid design-test cycles, antibiotic-free systems, and is capable of large, sophisticated molecular constructs to enable complex engineering.
Our platforms scalability and predictability, coupled with ongoing advancements, position KOMO as a leader in genome engineering. KOMOs technology will accelerate the efforts of therapeutic developers, contract research and development manufacturing organizations, and government agencies through licensing agreements and strategic partnerships.
